Does HSD11B1 convert cortisone to cortisol, and does rs12086634 reduce its activity?

The regulation of local glucocorticoid availability is a critical determinant of tissue-specific metabolic and inflammatory signaling. The enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) and its regulatory genetic variants, such as rs12086634, serve as primary physiological checkpoints in this pathway.

Tissue-specific cortisol activation

• Local glucocorticoid amplification: In vivo, HSD11B1 functions predominantly as an oxo-reductase, converting inactive cortisone into active cortisol within peripheral target tissues, including the liver, visceral adipose depots, skeletal muscle, and brain.
• Systemic contribution: This intracellular reactivation is highly efficient; HSD11B1-mediated reactivation in the liver and splanchnic bed alone contributes approximately 20% to 40% of the daily pool of circulating active cortisol.

Molecular and genetic mechanisms

• Cofactor dependency: The oxo-reductase directionality of HSD11B1 inside the endoplasmic reticulum lumen is driven by high local concentrations of NADPH. This cofactor supply is maintained by hexose-6-phosphate dehydrogenase (H6PD), which generates the NADPH required to reduce cortisone to cortisol.
• Genetic modulation by rs12086634: The single nucleotide polymorphism rs12086634 is a functional cis-regulatory expression quantitative trait locus (eQTL) located in an intronic enhancer of the HSD11B1 gene.
• Allele-specific activity: Molecular assays and tissue analyses confirm that the G allele at rs12086634 drives lower transcriptional activity and reduced local cortisol regeneration compared to the T allele, which is associated with elevated HSD11B1 transcript levels in adipose tissue.

Bottom line

• The biochemical conversion of inactive cortisone to active cortisol by HSD11B1 acts as a key local amplifier of glucocorticoid signaling, and the G allele of the rs12086634 polymorphism functionally reduces this enzyme's transcriptional and metabolic activity.